trials
Lpath Inc. (LPTN.OB) Secures Strategic $23M Alliance to Launch Cancer Treatment Trials
Read the full article: http://Blog.QualityStocks.net/?p=13172
Oftentimes money can stand in the way of health. In light of our current economic woes, many individuals find that the rising cost of healthcare outweighs the need for insurance and proper care. The same goes for scientific and medical companies in need of funding for further research and development.
- Login or register to post comments
- Read more
- Email this page
Related Articles
- Lpath Inc. (LPTN.OB) Secures Strategic $23M Alliance to Launch Cancer Treatment Trials
- GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
- China Pharma Holdings Inc. (CPHI.OB) Posts Positive Q3 Results Across the Board
- CardioVascular Biotherapeutics Inc. (CVBT.OB) Finds Significant Private Funding for Topical Diabetic Wound Care Rollout
- China Yongxin Pharmaceuticals Inc. (CYXN.OB) is “One to Watch”